Trial purpose
Cancer treatment
Tumor type
Lung cancer
Age
18+
Clinical summary
Summary
Eligible participants will be randomly allocated to receive MORAb-202 at either Dose Level 1 or Dose Level 2.
Conditions
This trial is treating patients with non-small cell lung cancer adenocarcinoma
Eligibility
Inclusion
- Histologically or cytologically documented metastatic NSCLC AC (as defined by the 8th International Association for the Study of Lung Cancer Classification).
- Measurable target disease assessed by the investigator according to RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Exclusion
- NSCLC histologies other than AC (ie, squamous cell carcinoma, large cell carcinoma).
- Significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage.
- Prior pneumonectomy. Prior lobectomy and segmentectomy are allowed > 12 months before treatment.
- Recent chest radiotherapy. Participants with chest or chest wall radiation may be permitted if chest radiation is documented > 6 months before starting study treatment.
Other protocol-defined inclusion/exclusion criteria apply.
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Bristol-Myers Squibb (BMS)
Scientific Title
A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Cancer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
Get support
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
More info for carers